ISIN | CH0113817123 |
---|---|
Valor Number | 11381712 |
Bloomberg Global ID | BBG0017T9CY3 |
Fund Name | Bellevue Biotech DT CHF |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland | |
Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Switzerland |
Issuing Condition | Special conditions apply to the issue of units |
Redemption Condition | Special conditions apply to the redemption of units |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 3,725.99 CHF | 14.11.2024 |
---|---|---|
Previous Price * | 3,779.20 CHF | 13.11.2024 |
52 Week High * | 3,918.46 CHF | 16.07.2024 |
52 Week Low * | 3,036.19 CHF | 28.11.2023 |
NAV * | 3,725.99 CHF | 14.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 31,076,546 | |
Unit/Share Assets *** | 11,242,102 | |
Trading Information SIX |
YTD Performance | +10.85% |
29.12.2023 - 14.11.2024
29.12.2023 14.11.2024 |
---|---|---|
1 month | -0.34% |
14.10.2024 - 14.11.2024
14.10.2024 14.11.2024 |
3 months | +3.50% |
14.08.2024 - 14.11.2024
14.08.2024 14.11.2024 |
6 months | +6.15% |
14.05.2024 - 14.11.2024
14.05.2024 14.11.2024 |
1 year | +19.59% |
14.11.2023 - 14.11.2024
14.11.2023 14.11.2024 |
2 years | -2.14% |
14.11.2022 - 14.11.2024
14.11.2022 14.11.2024 |
3 years | -10.42% |
15.11.2021 - 14.11.2024
15.11.2021 14.11.2024 |
5 years | +18.66% |
14.11.2019 - 14.11.2024
14.11.2019 14.11.2024 |
Equity Participation Rate in % | 82.51 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | 16.6695 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date | 14.11.2024 |
Regeneron Pharmaceuticals Inc | 8.13% | |
---|---|---|
Amgen Inc | 8.00% | |
Vertex Pharmaceuticals Inc | 7.10% | |
Gilead Sciences Inc | 6.96% | |
AstraZeneca PLC ADR | 4.47% | |
Alnylam Pharmaceuticals Inc | 3.44% | |
argenx SE ADR | 2.78% | |
Illumina Inc | 2.54% | |
Insmed Inc | 2.02% | |
Ionis Pharmaceuticals Inc | 1.86% | |
Last data update | 31.08.2024 |
TER | 1.21% |
---|---|
TER date | 29.09.2023 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.21% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |